(Q24242995)

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Prolonged aldose reductase inhibition in chronic peripheral diabetic neuropathy: effects on microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

A 12-Month Randomized Controlled Study of the Aldose Reductase Inhibitor Ponalrestat in Patients with Chronic Symptomatic Diabetic Neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

A Controlled Trial of Sorbinil, an Aldose Reductase Inhibitor, in Chronic Painful Diabetic Neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Hypoxic neuropathy: does hypoxia play a role in diabetic neuropathy? The 1988 Robert Wartenberg lecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Clinical potential of aldose reductase inhibitors in diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Mechanisms of disease: mitochondria as new therapeutic targets in diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Polyol pathway and diabetic peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Treatment of diabetic polyneuropathy: Update 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Tolrestat for Mild Diabetic Neuropathy: A 52-Week, Randomized, Placebo-Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Tolrestat in the Primary Prevention of Diabetic Neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

The sorbinil retinopathy trial: neuropathy results. Sorbinil Retinopathy Trial Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

Metabolic and vascular factors in the pathogenesis of diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

Preventive foot care in people with diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

Natural progression of diabetic peripheral neuropathy in the Zenarestat study population

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004572.PUB2

7 January 2021

Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD002182

Identifiers

DOI

10.1002/14651858.CD004572.PUB2

1 reference

Consolidated OpenCitations Corpus – April 2017

2106201

2106201

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference